EXENATIDE MANUFACTURING AGREEMENTExenatide Manufacturing Agreement • July 15th, 2004 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT effective October 1, 2003, the (“Effective Date”) is made by and between Amylin Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 9360 Towne Centre Drive, Suite 110, San Diego, California 92121 (“AMYLIN”) and Mallinckrodt Inc., a Delaware corporation, having a principal place of business at 675 McDonnell Blvd., St. Louis, Missouri 63134 (“MALLINCKRODT”).
EXENATIDE MANUFACTURING AGREEMENTExenatide Manufacturing Agreement • March 12th, 2004 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AGREEMENT effective October 1, 2003, the (“Effective Date”) is made by and between Amylin Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 9360 Towne Centre Drive, Suite 110, San Diego, California 92121 (“AMYLIN”) and Mallinckrodt Inc., a Delaware corporation, having a principal place of business at 675 McDonnell Blvd., St. Louis, Missouri 63134 (“MALLINCKRODT”).
SIXTH AMENDMENT TO EXENATIDE MANUFACTURING AGREEMENTExenatide Manufacturing Agreement • August 3rd, 2012 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations
THIS SIXTH AMENDMENT to the Exenatide Manufacturing Agreement (the “Sixth Amendment”) originally made and entered into as of October 1, 2003, by and between Amylin Pharmaceuticals, Inc. (“AMYLIN”) and Mallinckrodt LLC (formerly known as Mallinckrodt Inc.) (“MALLINCKRODT”), as amended effective on and as of January 1, 2006, February 12, 2007, January 1, 2008, January 8, 2010 and February 14, 2011 (the “Supply Agreement”), is made and entered into between AMYLIN and MALLINCKRODT effective on and as of June 25, 2012 (except as and to the extent explicitly otherwise stated in this Sixth Amendment).
